Jazz Phase III Success With Xywav In Idiopathic Hypersomnia Strengthens A Valuable Franchise
Executive Summary
The company plans to file for approval in the expanded indication, for which there are currently no approved therapies.
You may also be interested in...
Zepzelca To Help Diversify Jazz Pharma's Portfolio, Revenue Base
Licensed from PharmaMar for the US market at the start of the year, Jazz Pharmaceuticals is hoping its new small-cell lung cancer therapy, Zepzelca (lurbinectedin), may have potential for other cancer types and in different combinations.
Pfizer's Bourla Urges Patience As COVID-19 Vaccine Data Timeline Lags
Highly anticipated data from Pfizer's Phase III COVID-19 vaccine trial does not appear on track to be made publicly available in October as previously expected.
All Eyes On Pfizer For More Details On COVID-19 Vaccine Launch
Pfizer's COVID-19 vaccine is sure to dominate the third quarter results call, with everything from data to widescale distribution and the potential financial reward on the minds of investors and the public.
Existing Subscriber?
Sign in to continue reading.
Need a specific report? 1000+ reports available
Buy Reports
Need a specific report? 1000+ reports available
Buy Reports